terilafon

Terilafon is a small molecule neuroprotective agent and free radical scavenger developed by Nanjing Zhongrui Pharmaceutical for the treatment of acute cerebral infarction (ischemic stroke). As a pyrazolone derivative, it is structurally and functionally related to edaravone but is classified as an innovative (Class 1) drug in China. Terilafon is designed to mitigate oxidative stress and neuronal injury during the acute phase of a stroke by scavenging reactive oxygen species (ROS), such as hydroxyl radicals, which are primary drivers of lipid peroxidation and cell membrane damage in the ischemic penumbra. The drug is administered via intravenous injection, with clinical protocols evaluating both loading and maintenance dosing strategies to optimize therapeutic blood levels.

Other names

特立拉奉